Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 706

1.

Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells.

Yuan TC, Veeramani S, Lin FF, Kondrikou D, Zelivianski S, Igawa T, Karan D, Batra SK, Lin MF.

Endocr Relat Cancer. 2006 Mar;13(1):151-67.

2.

Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation.

Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ.

Prostate. 2002 Mar 1;50(4):203-15.

PMID:
11870798
3.
5.

Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.

Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schröder FH, van Steenbrugge GJ.

Cancer Res. 2000 Feb 1;60(3):741-8. Erratum in: Cancer Res 2000 Apr 1;60(7):2064.

6.

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models.

Denmeade SR, Sokoll LJ, Dalrymple S, Rosen DM, Gady AM, Bruzek D, Ricklis RM, Isaacs JT.

Prostate. 2003 Mar 1;54(4):249-57.

PMID:
12539223
7.

NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice.

Jin RJ, Wang Y, Masumori N, Ishii K, Tsukamoto T, Shappell SB, Hayward SW, Kasper S, Matusik RJ.

Cancer Res. 2004 Aug 1;64(15):5489-95.

8.

Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells.

Yuan TC, Veeramani S, Lin MF.

Endocr Relat Cancer. 2007 Sep;14(3):531-47. Review.

9.
11.

Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates 'neuroendocrine phenotype' in LNCaP prostate tumor cells.

Berenguer C, Boudouresque F, Dussert C, Daniel L, Muracciole X, Grino M, Rossi D, Mabrouk K, Figarella-Branger D, Martin PM, Ouafik L.

Oncogene. 2008 Jan 17;27(4):506-18. Epub 2007 Jul 16.

PMID:
17637748
12.

Establishment and characterization of androgen-independent human prostate cancer LNCaP cell model.

Igawa T, Lin FF, Lee MS, Karan D, Batra SK, Lin MF.

Prostate. 2002 Mar 1;50(4):222-35.

PMID:
11870800
13.

A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential.

Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ.

Cancer Res. 2001 Mar 1;61(5):2239-49.

14.

Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines.

Rocchi P, Boudouresque F, Zamora AJ, Muracciole X, Lechevallier E, Martin PM, Ouafik L.

Cancer Res. 2001 Feb 1;61(3):1196-206.

16.

Valproic acid induces neuroendocrine differentiation and UGT2B7 up-regulation in human prostate carcinoma cell line.

Valentini A, Biancolella M, Amati F, Gravina P, Miano R, Chillemi G, Farcomeni A, Bueno S, Vespasiani G, Desideri A, Federici G, Novelli G, Bernardini S.

Drug Metab Dispos. 2007 Jun;35(6):968-72. Epub 2007 Mar 19.

17.

[The influence of neuroendocrine differentiation on the growth and androgen receptor expression of prostate carcinoma cells].

Song Y, Wu G, Xin DQ, Na YQ.

Zhonghua Wai Ke Za Zhi. 2004 Dec 7;42(23):1453-6. Chinese.

PMID:
15733464
18.

The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.

Mosca A, Berruti A, Russo L, Torta M, Dogliotti L.

J Endocrinol Invest. 2005;28(11 Suppl International):141-5. Review.

PMID:
16625864
19.
20.

Supplemental Content

Support Center